AVALO THERAPEUTICS INC (AVTX) Stock Fundamental Analysis
USA - NASDAQ:AVTX - US05338F3064 - Common Stock
17.57 USD
-0.35 (-1.95%)
17.57 USD
0 (0%)
AVTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVTX as it has an excellent financial health rating, but there are worries on the profitability. AVTX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AVTX had negative earnings in the past year.
In the past year AVTX has reported a negative cash flow from operations.
AVTX had negative earnings in each of the past 5 years.
AVTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AVTX (-41.34%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -46.84%, AVTX is in the better half of the industry, outperforming 67.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.34% | ||
| ROE | -46.84% | ||
| ROIC | N/A |
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AVTX's Gross Margin of 201.13% is amongst the best of the industry. AVTX outperforms 99.44% of its industry peers.
In the last couple of years the Gross Margin of AVTX has grown nicely.
AVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 201.13% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
2. Health
2.1 Basic Checks
AVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AVTX has been increased compared to 1 year ago.
The number of shares outstanding for AVTX has been increased compared to 5 years ago.
AVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.44 indicates that AVTX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.44, AVTX is in the better half of the industry, outperforming 72.47% of the companies in the same industry.
AVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.44 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
AVTX has a Current Ratio of 19.96. This indicates that AVTX is financially healthy and has no problem in meeting its short term obligations.
AVTX has a Current ratio of 19.96. This is amongst the best in the industry. AVTX outperforms 94.19% of its industry peers.
A Quick Ratio of 19.96 indicates that AVTX has no problem at all paying its short term obligations.
AVTX has a Quick ratio of 19.96. This is amongst the best in the industry. AVTX outperforms 94.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.96 | ||
| Quick Ratio | 19.96 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 95.84% over the past year.
AVTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -77.08%.
The Revenue for AVTX have been decreasing by -42.05% on average. This is quite bad
EPS 1Y (TTM)95.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.35%
Revenue 1Y (TTM)-77.08%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, AVTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.65% on average per year.
AVTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 111.61% yearly.
EPS Next Y96.35%
EPS Next 2Y40.19%
EPS Next 3Y25.54%
EPS Next 5Y14.65%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y111.61%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AVTX's earnings are expected to grow with 25.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.19%
EPS Next 3Y25.54%
5. Dividend
5.1 Amount
No dividends for AVTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.57
-0.35 (-1.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.69%
Inst Owner Change0%
Ins Owners4.82%
Ins Owner Change0%
Market Cap231.05M
Revenue(TTM)441.00K
Net Income(TTM)-62310000
Analysts86.67
Price Target32.93 (87.42%)
Short Float %10.95%
Short Ratio3.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-946.48%
Min EPS beat(2)-1889.97%
Max EPS beat(2)-2.98%
EPS beat(4)0
Avg EPS beat(4)-3403.42%
Min EPS beat(4)-11614.9%
Max EPS beat(4)-2.98%
EPS beat(8)3
Avg EPS beat(8)-1969.42%
EPS beat(12)5
Avg EPS beat(12)-1307.29%
EPS beat(16)7
Avg EPS beat(16)-984.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.63%
PT rev (3m)4.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 523.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.74 | ||
| P/tB | 1.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-12.37
EYN/A
EPS(NY)-5.69
Fwd EYN/A
FCF(TTM)-3.73
FCFYN/A
OCF(TTM)-3.73
OCFYN/A
SpS0.03
BVpS10.12
TBVpS9.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.34% | ||
| ROE | -46.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 201.13% | ||
| FCFM | N/A |
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 19.96 | ||
| Quick Ratio | 19.96 | ||
| Altman-Z | 4.44 |
F-Score5
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)52.94%
Cap/Depr(5y)33.74%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.35%
EPS Next Y96.35%
EPS Next 2Y40.19%
EPS Next 3Y25.54%
EPS Next 5Y14.65%
Revenue 1Y (TTM)-77.08%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y111.61%
EBIT growth 1Y-96.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-59.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.9%
OCF growth 3YN/A
OCF growth 5YN/A
AVALO THERAPEUTICS INC / AVTX FAQ
Can you provide the ChartMill fundamental rating for AVALO THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to AVTX.
Can you provide the valuation status for AVALO THERAPEUTICS INC?
ChartMill assigns a valuation rating of 1 / 10 to AVALO THERAPEUTICS INC (AVTX). This can be considered as Overvalued.
How profitable is AVALO THERAPEUTICS INC (AVTX) stock?
AVALO THERAPEUTICS INC (AVTX) has a profitability rating of 2 / 10.
What is the earnings growth outlook for AVALO THERAPEUTICS INC?
The Earnings per Share (EPS) of AVALO THERAPEUTICS INC (AVTX) is expected to grow by 96.35% in the next year.